Near 2x Improvement in RA Disease Activity with PrismRA

PrismRA helps rheumatologists get their patients to the treat-to-target goal of low disease activity or remission sooner by predicting if a patient with rheumatoid arthritis (RA) will inadequately respond to a TNFi prior to initiating therapy.

After first-line TNFi failure, second-line response rates for patients with RA decline from 15-35%.1-3 This demonstrates the importance of selecting the right biologic or target synthetic DMARD early in the patient’s treatment journey, which can be challenging given the number of comparable treatment options available.4-7 In the prospective clinical utility study to evaluate PrismRA, both patients with and without a prediction of inadequate response to TNFi therapies experienced significant improvement in disease activity when therapy selection was guided by PrismRA.8

*PrismRA result of inadequate response detected is categorized as either 1) patient has a 10% chance of responding to TNFi or 2) patient has a 5% chance of responding to TNFi. A low score does not ensure a positive response to TNFi therapies.

Patients with a prediction of inadequate response to TNFi who initiated a therapy with an alternative mechanism of action (altMOA) had a near 2x improvement in their CDAI score (14.2) at 6 months, compared to patients with the same prediction of inadequate response who initiated a TNFi (7.8).8 Patients without a prediction of inadequate response who initiated a TNFi experienced a 1.6x improvement in CDAI scores at 6 months (12.7), compared to patients who had a prediction of inadequate response to TNFi therapies (7.8).8

Implement PrismRA into your practice to guide your therapy selection and help get your patients to low disease activity sooner.